ライフサイエンスコーパス: clinical result

1 nd all-comer registries have shown excellent clinical results.

2 Biochemical profiling studies confirmed the clinical results.

3 target for sarcoma treatment based on early clinical results.

4 bitors of these pathways have yielded varied clinical results.

5 to mediate tumor eradication with impressive clinical results.

6 omy for achalasia does not improve or worsen clinical results.

7 uropathological data are consistent with the clinical results.

8 BZ further complicates any interpretation of clinical results.

9 hematological cancers has yielded impressive clinical results.

10 an be used to treat diffuse ISR with similar clinical results.

11 safely in the elderly with excellent midterm clinical results.

12 n hospitalization costs, length of stay, and clinical results.

13 approach to optical mammography and initial clinical results.

14 D4 cells and plasma HIV-1 RNA paralleled the clinical results.

15 scaffolds, their basic characteristics, and clinical results.

16 f masked to routine reference laboratory and clinical results.

17 ligand 1) interactions-is showing impressive clinical results.

18 he original benchwork to the most up-to-date clinical results.

19 rived sequences in cfDNA are consistent with clinical results.

20 pha pathway activation and underlie variable clinical results.

21 delays in the timely reporting of important clinical results.

22 zing antiplatelet therapy to attain superior clinical results.

23 de guidance on the interpretation of routine clinical results.

24 All analyses were blinded to imaging and clinical results.

25 n treatment criteria, study populations, and clinical results.

26 uring sorafenib resistance recapitulated the clinical results.

27 side PET tracers is important for evaluating clinical results.

28 t has shown promising experimental and early clinical results.

29 anterior radii of curvature, consistent with clinical results.

30 enSx/Alcon, and OptiMedica systems and early clinical results.

31 D may be critical to achieve more successful clinical results.

32 ore aggressive treatment will yield improved clinical results.

33 ive and resective therapies will enhance the clinical results achieved through these procedures.

34 Clinical results achieved with bimanual microincisional

35 ifferences were seen among the groups in the clinical results after 12 months.

36 n trial) have been associated with different clinical results after reperfusion for acute myocardial

37 Current strategies to improve clinical results and expand access to UCBT to a larger n

38 The promising clinical results and favorable data observed in SPECT su

39 literature was reviewed, with an emphasis on clinical results and future directions.

40 Clinical results and resource utilization from a randomi

41 edictions are quantitatively consistent with clinical results and suggest that clonogenic inactivatio

42 his review, the biologic principles, seminal clinical results, and avenues for future development of

43 In contrast with clinical results, animal studies showed significantly in

44 spects that require attention when reporting clinical results are addressed.

45 spects that require attention when reporting clinical results are addressed.

46 In many patients, the hemodynamic and clinical results are comparable to that of septal myecto

47 rapid development in the past 10 years, and clinical results are confirming outstanding results for

48 These seemingly disparate clinical results are consistent with novel unrecognized

49 Clinical results are consistent with preclinical predict

50 ese new treatment modalities and preliminary clinical results are discussed.

51 The clinical results are dominated by 1 very large recent tr

52 Initial clinical results are encouraging.

53 , long-term multivariable analyses of actual clinical results are needed to complement actuarial calc

54 Clinical results are promising, but the therapy has not

55 Photodynamic therapy (PDT) clinical results are promising; however, tumor recurrenc

56 compared to determine whether the different clinical results are related to differences in biologic

57 unities for therapeutic selectivity and some clinical results are remarkable.

58 Clinical results are reported after follow-up of 3 years

59 -genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeuti

60 nces may explain the apparent differences in clinical results between the two compounds.

61 llowing dual standards defining a successful clinical result: CAL gain > or =2.67 mm and radiographic

62 Excellent clinical results can be achieved with the MIDCAB techniq

63 that with good patient maintenance excellent clinical results can be achieved with various methods of

64 d pulmonary arterial and somatic growth with clinical results comparable to early surgical repair in

65 use of BBM in this study did not enhance the clinical result compared to OF alone.

66 , Pi-infected sites exhibited less favorable clinical results compared to sites which were not infect

67 Neurohistological data, together with clinical results, corroborate the existence of an SEG in

68 The authors analyzed the clinical results during the first 8 1/2 years' experienc

69 that successful treatment may guarantee good clinical results even in long term after this severe pos

70 nsultant pediatricians, who reviewed all the clinical results except the nitric oxide measurements, o

71 Mean month 9 results showed similar clinical results for attachment level gain (DH 0.7 mm; S

72 Atheroablation yields improved clinical results for balloon angioplasty (percutaneous t

73 are discussed, along with the techniques and clinical results for conventional and fast spin echo T2-

74 article seeks to compare the preclinical and clinical results for Doxil(R), PK1, Abraxane(R), Genexol

75 Clinical results for EGFR targeting with specific monocl

76 ombined, these results suggest that the poor clinical results for growth factor-based therapies for c

77 Though preliminary clinical results for IRE are promising, implementing IRE

78 t improve CTL persistence and lead to better clinical results for T cell-based immunotherapies.

79 umor growth and provide new insight into the clinical results from a phase 1 human clinical study of

80 pret and understand diverse experimental and clinical results from both normal and diseased hearts.

81 ating rat physiology with mouse genetics and clinical results from human by using the respective geno

82 Clinical results from the latest strategies for T-cell a

83 The recent improvement in clinical results has paralleled a renewed interest in is

84 more safely and effectively to cancers, yet clinical results have been unpredictable owing to limite

85 Clinical results have demonstrated almost complete resol

86 Clinical results have validated FXR as therapeutic targe

87 Considering the clinical results, hereditary NS patients presented a ten

88 arriers in GTR procedures yielded comparable clinical results; however, in this study, data analysis

89 scular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data

90 These co-clinical results identify predictive genetic biomarkers

91 e critical factors in obtaining a successful clinical result in implant patients.

92 The placebo effect yields beneficial clinical results in 60-90% of diseases that include angi

93 evolution of the surgical technique and the clinical results in a large group of patients with long

94 block the PD-1 pathway have shown promising clinical results in a significant number of advanced-sta

95 Preclinical and clinical results in advanced and adjuvant colorectal can

96 Early clinical results in CLL with other reversible and irreve

97 OLL barriers resulted in generally favorable clinical results in furcation defects, appeared to be be

98 For the time period reported, the best clinical results in furcations and infrabony defects occ

99 of technique success rate, complications and clinical results in long term follow up for computed tom

100 unction, and could explain the disappointing clinical results in many current gene transfer trials.

101 MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients.

102 However, encouraging clinical results in patients immunized with autologous t

103 l care and standard medical care had similar clinical results in patients with subacute low back pain

104 ne xenograft (BDX) have both shown favorable clinical results in reducing intrabony periodontal defec

105 tic agents, with encouraging preclinical and clinical results in solid tumors.

106 ight the importance of careful assessment of clinical results in the broad population of patients in

107 alol antiarrhythmic effects in vitro and the clinical results in the same patient.

108 argeted therapies have yielded disappointing clinical results in treatment of this cancer.

109 Dr. Sabiston's disappointment with clinical results in ulcerative colitis and familial poly

110 Current clinical results indicate that (a) both umbilical cord b

111 Clinical results indicate that not all patients benefit

112 These experimental and clinical results indicate that SREBP-1 is a potential on

113 This clinical result is supported by in vitro studies of HERG

114 ts evidence that trainees can obtain similar clinical results like expert surgeons in laparoscopic co

115 Clinical results may suffer unless consideration is give

116 nation of histologic results (if available), clinical results (medical history, physical examination,

117 iprotafib pharmacology and interpretation of clinical results must be seen in light of this complexit

118 this group have experienced continuing good clinical results (New York Heart Association class I or

119 Clinical results now confirm that these new reagents, wh

120 blue TOF also contribute to the spectrum of clinical results observed after surgery.

121 need for caution when attempting to compare clinical results obtained at different institutions and

122 These results are consistent with the clinical results obtained from the patient treated with

123 The promising clinical results obtained with engineered T cells, inclu

124 es of the individual agents, may improve the clinical results obtained with FTIs.

125 athway ablation alone cannot account for the clinical results obtained with radiofrequency modificati

126 procedure did not significantly enhance the clinical results obtained with the GTR procedure alone.

127 We review these findings as well as the clinical results obtained with the Maze procedure.

128 h ticlopidine-containing regimens, the acute clinical results of "suboptimal" stent deployment are cl

129 Review the clinical results of 24 years of intestinal lengthening p

130 s multicenter trial demonstrates the initial clinical results of a new SPECT perfusion imaging modali

131 This study sought to evaluate the clinical results of a percutaneous approach to mitral va

132 Promising clinical results of administration of an Ab specific for

133 thus resembling to a degree prior phase III clinical results of bevacizumab plus paclitaxel in MBC.

134 The rationale, application and clinical results of each of these techniques are reviewe

135 Taken together with the 3-year clinical results of EXCEL, these findings suggest that P

136 We compared the mechanisms and clinical results of excimer laser coronary angioplasty (

137 Improving the clinical results of gene therapy for ADA deficiency and

138 We caution against the overinterpretation of clinical results of genomic testing in the absence of a

139 Lack of expected clinical results of IDDS therapy necessitates search for

140 In addition, we present unpublished clinical results of individual patient recordings and pr

141 The authors assessed the clinical results of lipid-lowering therapy in women.

142 cal or systemic antimicrobials would improve clinical results of non-surgical periodontal therapy for

143 Longer-term (1 to 5 years) clinical results of Palmaz-Schatz stenting are not yet w

144 This study was performed to determine the clinical results of patients with Crohns disease who req

145 rt-term (1 year) and long-term (2 to 5 year) clinical results of regenerative therapy in clinical pri

146 However, clinical results of single-agent PI3K inhibitors have be

147 le reviews the design, methodology and early clinical results of studies investigating the use of all

148 We report our initial clinical results of successful renal uptake reduction in

149 Registry was designed to assess the initial clinical results of the Edwards SAPIEN valve in consecut

150 isons and to report the arrhythmia detection clinical results of the PR Logic dual-chamber detection

151 eview describes the preclinical features and clinical results of the two major taxanes, paclitaxel (T

152 Here, we review the biology and clinical results of these five species of viruses and di

153 The clinical results of this comparative study have been pre

154 We evaluated the clinical results of this technique using a large, worldw

155 rminants, and a means to further improve the clinical results of transplantation from HLA-matched unr

156 aim of the present report is to present the clinical results of treating a dental implant using reco

157 wo observers in consensus and blinded to the clinical results performed image analysis of the arteria

158 nthesis in the PFC, and corroborate previous clinical results pointing to finasteride as a novel ther

159 After early unsatisfactory clinical results, polymeric HVs did not reach commercial

160 In this review, clinical results, proposed underlying mechanisms, and fu

161 Herein, we review clinical results reflecting the investigational use of C

162 Promising agents with preclinical and early clinical results relevant to aggressive skin SCC deserve

163 However, their value in predicting clinical results remains to date poorly defined.

164 ying visual quality and function by unifying clinical results reported using contrast sensitivity.

165 Our preclinical and clinical results revealed no statistically significant d

166 Our first clinical results should now be prospectively evaluated i

167 Our initial clinical results show that the frequency-domain scanner,

168 In conclusion, our clinical results show that the homozygous p.Ala467Thr PO

169 RM1 nuclear export/import may explain recent clinical results showing that highly malignant tumors ha

170 In accordance with the clinical results shown, we encourage further investigati

171 In conformity with clinical results, strong secondary responses were genera

172 Early clinical results suggest a possible role of this antisen

173 These in vitro and in vivo pre-clinical results suggest that a low dose of acutely admi

174 Animal studies and preliminary clinical results suggest that protein C/activated protei

175 Early clinical results suggest that the use of alternative don

176 usion, pharmacodynamic end points along with clinical results suggest usefulness of this combination

177 Olanzapine demonstrated clinical results superior to those of haloperidol on ove

178 The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PD

179 Available clinical results support the possibility that effects of

180 The clinical results support the use of monitoring for overa

181 Preliminary clinical results support these preclinical data and esta

182 ding peptide combined with ABM yields better clinical results than either DFDBA or DEBR.

183 periodontitis, achieves significantly better clinical results than initial periodontal treatment alon

184 ding peptide combined with ABM yields better clinical results than the ABM alone in intrabony periodo

185 We also describe preclinical and clinical results that indicate manipulation of CTLA-4 ha

186 blockade has shown promising preclinical and clinical results, therapeutic CD4(+)CD25(+) T reg cell d

187 Despite promising clinical results, these engineered T cells can exhibit e

188 n tested in phase 2 trials, with only modest clinical results thus far.

189 of these agents as anticancer therapeutics, clinical results to date, and developmental challenges t

190 lung cancer have produced only disappointing clinical results to date.

191 apolation from preclinical studies and first clinical results to select optimal doses and regimens of

192 and OF surgeries produced stable and similar clinical results up to 12 months.

193 Encouraging early clinical results using blocking agents against component

194 We describe initial promising clinical results using streptavidin-antibody constructs

195 Hands-on labor time for each clinical result was estimated to be at 7.5 min.

196 Consistent with these clinical results we found that intracerebral injection o

197 Owing to biological and clinical results, we concluded that an autoimmune mechan

198 , explaining the likely reasons for the poor clinical results; we then describe the use of the same c

199 Clinical results were analyzed for all randomly assigned

200 performed after profiling, and 42 patients' clinical results were available, 24 of which were used f

201 According to the Macnab criteria, the clinical results were classified as excellent in 92 (86%

202 Clinical results were determined at month 9.

203 melanoma patients whose mean IFN dosage and clinical results were directly taken from E1684 were inc

204 penter syndrome in the two individuals whose clinical results were presented in the original descript

205 Results Clinical results were similar in the two Japanese trials

206 Clinical results were worse with meniscal extrusion, wit

207 rferon-beta and ribavirin and show promising clinical results when administered in all-oral combinati

208 cians and patients suggested a more esthetic clinical result with AD.

209 The direct cost of each clinical result with CA was estimated to be $9.09.

210 BMS-ISR, both DEB and EES provided excellent clinical results with a very low rate of clinical and an

211 easurements demonstrated essentially similar clinical results with both treatments for bone and soft

212 Clinical results with FLT3 inhibitor monotherapy have sh

213 Preliminary clinical results with gOKT4A-4 suggest that we have elim

214 Despite the excellent clinical results with imatinib in chronic myeloid leukem

215 Despite encouraging clinical results with next generation drugs (MDV3100 and

216 ings of this study suggest essentially equal clinical results with PG bone replacement graft material

217 study, we prospectively analyzed the 5-year clinical results with the Freestyle valve (Medtronic, In

218 therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the an

219 ventive agents in this site, achieving mixed clinical results (with 13-cis-retinoic acid and etretina

220 od or bone marrow cells, which can produce a clinical result within a working day.

221 format with a single master mix and provides clinical results within 2 days.